Lineage: Surges as cancer vaccine shows promise in early-stage study

Lineage Cell Therapeutics

13/10/2020 18:37

** Shares of clinical-stage cell therapy developer  LCTX.A 
rise 9.4% to $1.16, its highest in four months
    ** LCTX says its cancer vaccine candidate, VAC2, showed
potential to induce immune responses in all dosed patients with
non-small cell lung cancer, according to preliminary results
from ongoing early-stage study  urn:newsml:reuters.com:*:nBw79DW5Ya
    ** Plans to test VAC2 in combination with complementary
treatments such as chemotherapy and a type of immunotherapy 
    ** Up to Monday's close, stock up 19.1% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))